Bone regeneration with umbilical cord blood mesenchymal stem cells in femoral defects of ovariectomized rats

Boohwi Hong a, Sunyeul Lee a, Nara Shin b, Youngkwon Ko a, DongWoon Kim b, Jun Lee c, Wonhyung Lee a, *

a Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon, Korea
b Department of Anatomy, Brain Research Institute, Chungnam National University School of Medicine, Daejeon, Korea
c Department of Orofacial Surgery, Wonkwang Dental Hospital, Daejeon, Korea

ABSTRACT

Objectives: Current treatments for osteoporosis were prevention of progression, yet it has been questionable in the stimulation of bone growth. The mesenchymal stem cells (MSCs) treatment for osteoporosis aims to induce differentiation of bone progenitor cells into bone-forming osteoblasts. We investigate whether human umbilical cord blood (hUCB)-MSCs transplantation may induce bone regeneration for osteoporotic rat model induced by ovariectomy.

Methods: The ovariectomized (OVX) group (n = 10) and OVX-MSCs group (n = 10) underwent bilateral ovariectomy to induce osteoporosis, while the Sham group (n = 10) underwent sham operation at aged 12 weeks. After a femoral defect was made at 9 months, Sham group and OVX group were injected with Hartmann solution, while the OVX-MSCs group was injected with Hartmann solution containing 1 x 10^7 hUCB-MSCs. The volume of regenerated bone was evaluated using micro-computed tomography at 4 and 8 weeks postoperation.

Results: At 4- and 8-week postoperation, the OVX group (5.0% ± 1.5%; 6.1% ± 0.7%) had a significantly lower regenerated bone volume than the Sham group (8.6% ± 1.3%; 12.0% ± 1.8%, P < 0.01), respectively. However, there was no significant difference between the OVX-MSCs and Sham groups. The OVX-MSCs group resulted in about 53% and 65% significantly higher new bone formation than the OVX group (7.7% ± 1.9%; 10.0% ± 2.9%, P < 0.05).

Conclusions: hUCB-MSCs in bone defects may enhance bone regeneration in osteoporotic rat model similar to nonosteoporotic bone regeneration. hUCB-MSCs may be a promising alternative stem cell therapy for osteoporosis.

© 2018 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Osteoporosis is one of the major systemic skeletal diseases worldwide today and is characterized by compromised bone strength resulting in bone fragility and heightened risk of bone fractures [1]. Osteoporotic patients experience low bone mass and density with microarchitectural deterioration of bone tissue in which osteoblast function and levels are reduced while osteoclast bone resorption is augmented [2]. Although no longer regarded as age- or sex-dependent, the presence of osteoporosis, specifically primary osteoporosis, is rapidly rising among the elderly and postmenopausal women experiencing estrogen deficiency [3]. A wide range of treatment for osteoporosis currently exists, including antiresorptive or bone regenerating pharmacological agents and lifestyle changes towards an altered diet and increased physical activity [4]. Bisphosphonates, the predominant drug-based therapy that inhibits bone resorption, is commonly prescribed; however, long-term safety concerns and serious adverse effects, such as osteonecrosis of the jaw and atypical femoral fractures, have limited its use [5–8]. Moreover, most current drugs have shown to prevent the progression of osteoporosis yet are questionable in stimulating bone growth [9]. On the other hand, mesenchymal stem cells (MSCs) are a primary cell source for induction of bone regeneration and bone graft engineering [10]. These stem cells have the ability to self-renew and differentiate into multiple lineages, such as...
osteoblasts, chondrocytes, adipocytes and myocytes [11]. Physiologically, the occurrence of osteoporosis has been linked to a decrease in the osteogenic potential of MSCs in the bone marrow and periosteum [12–14], as shown by their diminished cell count and decreased ability to proliferate and differentiate into osteoblasts [13,15–17]. Thus, MSCs-based treatment of osteoporosis aims to induce differentiation and osteogenesis of bone progenitor cells into active, bone-forming osteoblasts.

Multiple tissues have been discovered to harbor MSCs, including bone marrow [18], adipose tissue [19], and umbilical cord blood [20]. Studies have reported encouraging results from MSCs transplantations performed in various osteoporotic models. Wang et al. [21] showed that bone-marrow derived MSCs transplantation enhanced trabecular thickness, bone apposition and osteoid formation, thus strengthening bone in ovariectomized (OVX) rabbit models. Moreover, Ye et al. [22] reported that adipose–derived stem cell transplantation promoted osteogenesis and inhibited adipogenesis of bone marrow mesenchymal stromal cells by activating bone morphogenetic protein 2 and additionally increased local bone mineral density in OVX rabbit models. MSCs obtained from human umbilical cord blood (hUCB) were shown to improve trabecular and bone formation parameters, hence preventing OVX-induced bone loss in mouse models [23].

MSCs from bone marrow aspirates are deemed to have the greatest multilineage potential, thus is commonly used for tissue engineering and regenerative medicine [24]. However, MSCs from this origin are obtained through an invasive, painful procedure and may decrease in differentiation potency after cultivation or with the donor’s age [25,26]. In contrast, hUCB provides a richer source of human MSCs [27] that displays low immunogenic potential [28] and may be harvested via simpler and noninvasive methods [29]. Moreover, hUCB derived MSCs are reported to exhibit higher proliferation rates [30] and greater capacity for osteogenic differentiation compared to other MSCs thus providing a strong rationale for the use of hUCB-derived MSCs (hUCB-MSCs) in stem cell regenerative therapy in bone-related diseases [31–33]. In this study, we aim to investigate whether hUCB-MSCs transplantation in femoral defects of OVX rats may help induce bone regeneration in osteoporotic rat models.

2. Methods

2.1. hUCB and mononuclear cell isolation

hUCB was obtained from a cord blood bank (LifeLine, Yongin, Korea). hUCB was drawn from the umbilical vein of newborns, collected into cord blood collection bags containing anticoagulant (Greencross LabCell Corp., Yongin, Korea), and stored at room temperature. Written informed consent was obtained from each parent. The mononuclear cells from hUCB were obtained by sterile a pyrogenic Ficoll–paque density gradient centrifugation (1.077 g/cm³, GE Healthcare, Chicago, IL, USA), according to the manufacturer’s instructions, and washed with phosphate buffered saline, and plated at 1 × 10⁶ cells/cm² in low glucose Dulbecco Modified Eagle Medium (Gibco, Seoul, Korea) supplemented with 30% fetal bovine serum (Gibco), 1% antibiotics–antimycotics (Gibco). After 7 days, non-adherent cells were discarded, and adherent cells were cultured with three medium replacements per week. The cells were grown at 37 °C in a humidified atmosphere containing 5% CO₂. Approximately 70% of confluent cells were detached with 0.05% trypsin ethylenediaminetetraacetic acid (EDTA; Gibco) and replated at a density of 3 × 10⁵ in a T175 culture flask. The hUCB-MSCs were also expanded in culture by repeated harvesting and replating of cells every seven days, up to the 10th passage.

For transplantation into animals, 1 × 10⁷ cells were collected at the 6th passage and resuspended in 7.5 μL of Hartmann solution (JW Pharmaceutical, Seoul, Korea) with 1% albumin (Greencross LabCell Corp., Yongin, Korea).

2.3. Characterization of hUCB-MSCs

hUCB-MSCs were characterized by the cell surface protein profile and the differentiation capability. The harvested cells were analyzed for the expression of CD73, CD105, CD44, HLA-ABC, CD90, CD13, CD166, CD45, CD34, HLA-DR by FACs laser cytometry (Beckman Coulter, Seoul, Korea). Approximately 0.5–1 × 10⁶ cells per tube were used for cell surface antigen expression studies. To evaluate differentiation capability of hUCB-MSCs, multi lineage differentiation tests were performed in vitro. For induction of osteogenic or adipogenic differentiation, 70% confluent cells were incubated in respective differentiation medium (Lonza). For induction of chondrogenic differentiation, the hUCB-MSCs pellet was incubated in a polypropylene tube containing commercially available chondrogenic differentiation medium (Lonza). After 3 weeks, the osteogenic differentiation ability was assessed by Von Kossa staining. After 4 weeks, adipogenic differentiation was assessed by oil red O staining. After 6 weeks, the harvested chondrogenic pellets were fixated with 10% formalin and paraffin embedded for histological processing. 5-μL-thin sections were stained with safranin O.

2.4. Osteoporotic rat model

All experimental procedures were approved by the Animal Experimentation Ethics Committee of Chungnam National University Hospital (CNUH-017-A0045). The female Sprague-Dawley rats aged 12 weeks were purchased from Daniel Science (Daejeon, Korea) and acclimated to conditions 1 week before and throughout the experimental period. The animals were housed in a room air-conditioned at 22 ± 2 °C with a 12-hour light/dark cycle and free access to commercial rodent diet.

OVX rats were used as osteoporotic models in this study [34]. The ovariectomy method utilized was the double dorso-lateral approach explained by Park et al. [35]. All animals at 12 weeks of age were randomly distributed into 3 groups: Sham group, OVX group, and OVX-MSCs group. The Sham group (n = 10) underwent Sham operation while the OVX (n = 10) and OVX-MSCs groups (n = 10) underwent bilateral ovariectomy to induce osteoporosis.

2.5. Femoral defect surgical methods

Six months following ovariectomy or sham operations (at 9 months of age), all rats underwent surgery creating a bone defect on right distal femurs of Sham rats and both left and right distal femurs on OVX rats. All rats were anaesthetized with isoflurane (Forane; Abbott Laboratories, North Chicago, IL, USA) at a 1:1 flow ratio of N₂O and O₂. Under sterile surgical conditions, linear incisions were made on the skin and subcutaneous tissue to expose the distal femoral bone. Using a micro motor 207A apparatus (HTY-M04 Saeshin Strong 207A + 107L; Hanen Hongtaiyang Medical Apparatus and Instruments Co., Ltd., Hanen, China), a defect cavity...
(1.2-mm diameter, 7-mm height) was created into the epiphysis using a rotary burr (1.2mm diameter, 7-mm height) under continuous saline irrigation to minimize overheating. Right femoral defects of Sham rats and OVX rats were injected with 7.5 μL of Hartmann solution. The right femoral defect of OVX-MSCs rats was injected with 7.5 μL of Hartmann solution containing 1 × 10^7 hUCB-MSCs. The gel-type adhesive (Greenplast Q, Greencross LabCell Corp., Yongin, Korea) was injected to fill the femoral defect and prevent leakage of solution. The subcutaneous tissue and muscle were closed using synthetic resorbable materials (4-0 Vicryl W9074; Ethicon, Somerville, NJ, USA). Outer skin was sutured with monofilament materials (2-0 Prolene W8623; Ethicon). Unrestricted movement and activity of the rat were observed postoperatively after recovery from anesthesia. At 4- and 8-week postoperation, 5 rats per group were euthanized and the left and right distal femur from each rat was isolated. Prior to microcomputed tomography (micro-CT) and histological analysis, samples were fixed in 4% paraformaldehyde solution for approximately 3–5 days.

2.6. Micro-CT analysis

The volume of regenerated bone was evaluated using micro-CT (Sky-Scan 1172 TM; Skyscan, Kontich, Belgium) scan under an X-ray voltage of 60 kV and a current of 167 μA using a 0.5-mm aluminum filter. The scanned data were reconstructed by image analysis software (CTAnalyzer; Skyscan, Kontich, Belgium). Measurements of radiopaque regions of interest relative to the entire defect volume were representative of the percent of bone volume formed.

2.7. Histological evaluation

The distal femoral specimens were decalcified in a 10% EDTA solution with a pH of 7.4 and dehydrated in a graded series of alcohol solutions (80%–100%). The specimens were then embedded in paraffin. Using a rotary microtome (HM 325; Microm, Walldorf, Germany), 5-μm sections of the samples were cut. Each specimen was stained with hematoxylin and eosin and then observed under a light microscope (DMR; Leica, Nussloch, Germany) equipped with a digital camera (DFC-480; Leica).

2.8. Statistical analysis

Quantitative measurements of newly formed bone was analyzed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). Because there is a small number of samples that are not normally distributed, Nonparametric analysis utilizing Kruskal-Wallis test and post hoc analysis by Mann-Whitney test was performed. P < 0.05 was considered statistically significant.

3. Results

3.1. Characterization of hUCB-MSCs

The in vitro expansion of hUCB-MSCs was observed under optical microscopy and confirmed the morphology of hUCB-MSCs as shown in Fig. 1A. The multilineage differentiation ability of hUCB-MSCs was demonstrated confirmed by positive staining for osteogenesis, adipogenesis and chondrogenesis after incubation in the respective differentiation mediums (Fig. 1B). Flow cytometry analyses showed that hUCB-MSCs were positive for MSCs-specific surface antigens CD73, CD105, CD29, CD90 and negative for hematopoietic cell-specific marker CD45, CD34, HLA-DR (Fig. 1C).

3.2. Animals

All animals underwent a successful recovery after operation. Moreover, histopathologic observations did not detect any necrosis.
in any specimens of this study.

3.3. Micro-CT analysis

Fig. 2A shows the reconstructed 3-dimensional image of the distal femur at 8-week postoperation as analyzed by micro-CT. The images show that the Sham group had a denser trabecular bone density in the epiphyses and metaphysis bone microstructure of the distal femur in contrast to the OVX group. Bone formation at the margins of the defect was observed in all experimental and Sham groups, although with varying degrees. Within the defect, OVX-MSCs group showed a greater amount of new bone formation in the central and marginal area of the defect compared to the OVX group. In contrast, the Sham group resulted with the most active and dense bone regeneration throughout the defect cavity.

Quantitative measurements of newly formed bone was represented by percent bone volume calculations from micro-CT analyses as depicted in Fig. 2B. At both 4- and 8-week postoperation, the OVX group (5.0% ± 1.5%) (6.1% ± 0.7%) had a significantly lower percent bone volume than the Sham group, respectively (8.6% ± 1.3%) (12.0% ± 1.8%) (P < 0.01). However, there was no significant difference in percent bone volume between the OVX-MSCs and Sham group at all time periods. The OVX-MSCs (7.7% ± 1.9%) resulted with about 53% significantly higher new bone formation than the OVX (P < 0.05). Likewise, at 8-week postoperation, the percent bone volume was significantly higher in the OVX-MSCs group (10.0% ± 2.9%) compared with the OVX group by approximately 65%. These results suggest that the presence of hUCB-MSCs in bone defects may enhance bone regeneration in osteoporotic environments to levels similar to that of nonosteoporotic bone.
3.4. Histological evaluation

Histologic images with hematoxylin and eosin staining of the distal femur at 8-week postoperatively are depicted in Fig. 3. The Sham group showed densely formed new trabecular bone within the defect area. The OVX-MSCs group showed thicker newly formed bone within the defect cavity as well as in the marginal regions.

4. Discussion

In our study, we demonstrated that local injection of hUCB-MSCs enhanced the ability of new bone formation in osteoporotic rats. By establishing an estrogen-deficient OVX rat model, we compared bone regeneration in femoral defects under both healthy and osteoporotic conditions. Because local injection of hUCB-MSCs in OVX models increased bone formation to levels comparable to nonosteoporotic models, we concluded that the presence of hUCB-MSCs may be a valuable alternative in stem cell therapy for osteoporosis.

The pathogenesis of osteoporosis stems from the imbalance in bone remodeling due to defects in osteoid-secreting osteoblasts and augmented function of proteolytic osteoclasts. The disease is prevalent among estrogen-deficient postmenopausal women who experience dramatically increased bone turnover rates and corresponding loss of bone mass [36]. Estrogen is an important steroid in maintaining adequate bone mass and architecture thus withdrawal may lead to irreversible loss of thin trabecular elements and heightened incidence of fractures [37]. Therefore, deprivation of estrogen through ovariectomy procedures has been frequently used to mimic postmenopausal osteoporosis in experimental animals. In this study, the OVX group showed distinct osteoporotic features in the distal epiphyseal and metaphyseal femur in contrast to the Sham group (Figs. 2A and 3). The micro-CT and histological results display significantly reduced trabecular density with greater porous features in the cancellous bone, thus demonstrate the establishment of osteoporosis in the rat models at 180 days postovariectomy. Likewise, previous reports confirm a time period of 180 days or longer after ovariectomy for cortical bone remodeling to simulate postmenopausal osteoporosis and result in a significant decrease in cancellous bone volume of up to 30%–35% in OVX rats [38,39].

MSCs extracted from various sources, including the bone marrow, adipose tissue, periosteum, and umbilical cord, have been previously utilized in bone regeneration and stem cell therapy for osteoporosis [29,40,41]. Diminished function and osteogenic potential of MSCs in the bone marrow and periosteum [12–14], demonstrated by reduced proliferation and osteodifferentiation, is normally coupled with osteoporosis [13,15–17]. Consequently, MSCs-based treatment aims to induce differentiation and osteogenesis of bone progenitor cells into active, bone-forming osteoblasts. Recently, MSCs-based methods have attracted much attention not only because of the cells’ self-renewal and pluripotent properties, but also due to their immunosuppressive capacity [42]. Bone marrow mesenchymal stromal cells were initially discovered to effectively differentiate into osteoblasts; however, the highly invasive harvesting procedure and the decline in proliferation and differentiation potential with increasing age have limited its clinical use [40,43]. On the other hand, hUCB-MSCs are harvested and stored via simpler methods [29] and have displayed higher osteogenicity and proliferation rates compared to other MSCs [30–32,40]. In addition, hUCB-MSCs were reported to actively inhibit the allogeneic proliferation of responder lymphocytes [44] and retain immunosuppressive activity equal to bone marrow- and adipose-derived MSCs [30].

In this study, OVX rats that received xenograft hUCB-MSCs developed 53% and 65% more bone volume in the femoral defect compared to OVX rats treated with saline at 4- and 8-week postoperation, respectively (Fig. 2). Moreover, there were no significant differences in the percent bone volume between the OVX-MSCs and Sham groups. Despite being a xenograft stem cell transplantation, we found no evidence of immunogenic rejection. In fact, when Oh et al. [44] pretreated hUCB-MSCs with interferon-γ and pro-inflammatory cytokines interleukin (IL)-1β or tumor necrosis factor-α, there was no inflammatory response provoked thus suggesting that hUCB-MSCs may be transplanted into inflammation regions without the necessary requirement of long-term immunosuppressive treatment. Furthermore, the secretion of immune inhibitory cytokines from hUCB-MSCs, including IL-10 and transforming growth factor-β, has also been previously discovered, hence concluding the mesenchymal content responsible for the tolerogenic characteristics of cord blood [45,46]. Analogous to these reports, our study suggests hUCB-MSCs xenotransplantations in bone defects of osteoporotic conditions may positively enhance bone regeneration abilities with minimal immunogenic responses.

Recently, there have been a few reports studying osteogenicity of hUCB-MSCs in vivo. Jo et al. [47] found that hUCB-MSCs attached on a scaffold in critical-sized femoral defects of rats showed significantly higher levels of osteogenesis than the scaffold-only group and the adipose tissue- and umbilical cord-derived MSCs group. Similar to our study, comparisons were based on total bone volume percentages, but additionally demonstrated significantly elevated trabecular numbers and radiologic scores in the hUCB-MSCs group [47]. Despite the poor engraftment of MSCs in bone

---

**Fig. 3.** Histological observations. Hematoxylin and eosin-stained histological morphology of the entire area of distal femurs 8 weeks after surgery. (A) Sham operation. (B) Ovariectomy. (C) Mesenchymal stem cells injected after ovariectomy. Asterisk, new bone. Scale bar is 1 mm. OVX, ovariectomized; OVX-MSCs, OVX-mesenchymal stem cells.
tissue after systemic administration, this study discovered increased serum procollagen type-I N-telopeptide levels, elevated alkaline phosphatase activity, and heightened pro-osteogenic mRNA expression; thus, they proposed that the prevention of OVX-mediated bone loss may be attenuated by a paracrine mechanism [23]. This mechanism may be a possible explanation behind the increased bone formation observed in our study after the injection of hUCB-MSCs. In fact, a recent clinical study has demonstrated significant increases in insulin-like growth factor 1 levels and beneficial effects on bone mineral density following subcutaneous injection of allogenic hUCB mononuclear cells in osteoporotic patients [48].

Although hUCB-MSCs have the potential to be differentiated into multiple cell lineages, studies have reported the relatively low ability to differentiate towards the adipocytic lineage compared to bone marrow- and adipose-derived MSCs [40,49]. Moreover, the expression of BMP receptors was discovered pre-porosis studies [54]. Therefore, rodents are the most common animal model for osteoporosis hence the lack of Haversian systems and remodeling in the Haversian system plays a minor role [53]. OVX-mediated bone loss may be attenuated by a paracrine mechanism through the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008;19:1683–704.

Acknowledgments

The authors thank student doctor Jaein Lee (Chungnam National University School of Medicine) for her invaluable contribution throughout this research. This study was partially supported by the National Research Foundation of Korea (2017R1A2B4005905).

References

[1] Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1–45.
[2] Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3138–25.
[3] Szczy P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008;19:1683–704.
[4] Das S, Crockett JC. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Dev Ther 2013;7:435–48.
[5] Khan AA, Sándor GK, Dore E, Morrison AD, Alsahl M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478–90.
[6] Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243–51.
[7] Saleh A, Hegde VV, Potty AG, Lane JM. Bisphosphonate therapy and atypical fractures. Orthop Clin N Am 2013;44:137–51.
[8] Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010;8:34–9.
[9] Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008;15:284–304.
[10] Fröhlich M, Grayson WL, Wan IQ, MaroI D, Drobnic M, Vujan-Nakoviovic G. Tissue engineered bone grafts: biological requirements, tissue culture and clinical relevance. Curr Stem Cell Res Ther 2008;3:254–64.
[11] Undale AH, Westendorf JJ, Yaszemski MJ, Rhoisa S. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc 2009;84:801–902.
[12] Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A, Loutradis D, et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cell Dev 2011;20:1549–61.
[13] Chen XD, Shi S, Xu T, Bobey PG, Young MF. Age-related osteoporosis in biglycan-deficient mice is resistant to defects in bone marrow stromal cells. J Bone Miner Res 2002;17:331–40.
[14] Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 2002;55:693–8.
[15] Mueller SM, Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001;82:583–90.
[16] Rodríguez JP, Garat S, Gajardo S, Pino AM, Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem 1999;75:414–23.
[17] Bonyadi M, Waldman SD, Liu D, Aubin JE, Grynpas MD, Stanford WL. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1-/Ly-6A null mice. Proc Natl Acad Sci U S A 2003;100:5840–5.
[18] Bianco P. Stem cells and bone: a historical perspective. Bone 2015;70:2–9.
[19] Zok PA, Zhou M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211–28.
[20] Ercis A, Conger P, Minguell J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235–42.
[21] Wang Z, Goh J, Dui De S, Ge Z, Ouyang H, Chong JS, et al. Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 2006;12:1753–61.
[22] An JH, Park H, Song JA, Ki KH, Yang JY, Choi HJ, et al. Transplantation of human umbilical cord blood-derived mesenchymal stem cells in strengthening osteoporotic bone in a rabbit model. Cell Transplantation 2013;22:1643–55.
[23] Ash DJ, Park H, Song JA, Kim JH, Sung YK, et al. Transplantation of human umbilical cord blood-derived mesenchymal stem cells in strengthening osteoporotic bone in a rabbit model. Cytotechnology 2014;66:1431–45.
[24] Sanderup K, Justesen C, Clausen K, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33:919–26.
[25] Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, et al.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.
